Alopecia Areata — PAI-1 Expression in Non-scarring Hair Loss
Citation(s)
Angleton P, Chandler WL, Schmer G Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation. 1989 Jan;79(1):101-6.
Bahta AW, Farjo N, Farjo B, Philpott MP Premature senescence of balding dermal papilla cells in vitro is associated with p16(INK4a) expression. J Invest Dermatol. 2008 May;128(5):1088-94. Epub 2007 Nov 8.
Balsara RD, Castellino FJ, Ploplis VA A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells. J Biol Chem. 2006 Aug 11;281(32):22527-36. Epub 2006 Jun 19.
Berkenpas MB, Lawrence DA, Ginsburg D Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 1995 Jul 3;14(13):2969-77.
Cash TF, Price VH, Savin RC Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol. 1993 Oct;29(4):568-75.
Cash TF The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol. 1992 Jun;26(6):926-31.
Kortlever RM, Higgins PJ, Bernards R Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol. 2006 Aug;8(8):877-84. Epub 2006 Jul 23.
Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010 Oct;146(10):1141-50. doi: 10.1001/archdermatol.2010.256. Review.
Mounsey AL, Reed SW Diagnosing and treating hair loss. Am Fam Physician. 2009 Aug 15;80(4):356-62. Review.
Norwood OT Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg. 2001 Jan;27(1):53-4.
Ogunmakin KO, Rashid RM Alopecia: the case for medical necessity. Skinmed. 2011 Mar-Apr;9(2):79-84. Review.
Rathnayake D, Sinclair R Male androgenetic alopecia. Expert Opin Pharmacother. 2010 Jun;11(8):1295-304. doi: 10.1517/14656561003752730. Review.
Rogers NE, Avram MR Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008 Oct;59(4):547-66; quiz 567-8. doi: 10.1016/j.jaad.2008.07.001. Review.
Scheinfeld N A review of hormonal therapy for female pattern (androgenic) alopecia. Dermatol Online J. 2008 Mar 15;14(3):1. Review.
Schweiger ES, Boychenko O, Bernstein RM Update on the pathogenesis, genetics and medical treatment of patterned hair loss. J Drugs Dermatol. 2010 Nov;9(11):1412-9. Review.
Simonetti O, Lucarini G, Bernardini ML, Simoncini C, Biagini G, Offidani A Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study. Br J Dermatol. 2004 May;150(5):940-8.
Trüeb RM Oxidative stress in ageing of hair. Int J Trichology. 2009 Jan;1(1):6-14. doi: 10.4103/0974-7753.51923.
Vaughan DE, De Taeye BM, Eren M PAI-1 antagonists: predictable indications and unconventional applications. Curr Drug Targets. 2007 Sep;8(9):962-70. Review.
Vaughan DE PAI-1 antagonists: the promise and the peril. Trans Am Clin Climatol Assoc. 2011;122:312-25.
Evaluating PAI-1 Expression in the Hair Follicles of Patients With Non-scarring Hair Loss.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
